NUVAXOVID arrives ready to use in prefilled syringes, with no freezing or thawing needed1
Ready to use—no dilution, mixing, or thawing required
Ships in a carton of 10 prefilled syringes, each containing 1 dose of 0.5 mL
Store in a standard refrigerator
Store prefilled syringes between 2 to 8 °C (36 to 46 °F)
Do not freeze. Protect from light.
Only store prefilled syringes in a standard refrigerator. Store in original carton to protect from light.
Follow the CDC-recommended dosing schedule when administering NUVAXOVID1-3
For patients aged 65+
Vaccinated with primary series of NUVAXOVID or with any other COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose at least 2 months after receipt of the previous vaccine dose1
- ACIP recommends patients should receive an additional dose 6 months after the previous dose (minimum interval of 2 months)2
Not previously vaccinated with any COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose1
- ACIP recommends patients should receive an additional dose 6 months after the previous dose (minimum interval of 2 months)2
For patients aged 12-64 with ≥1 underlying condition
Vaccinated with primary series of NUVAXOVID or with any other COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose at least 2 months after receipt of the previous vaccine dose1
Not previously vaccinated with any COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose
Are your high-risk patients eligible for NUVAXOVID?
NUVAXOVID is also indicated for individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.1
The NUVAXOVID pivotal trial included patients who were high risk for COVID-19 due to underlying conditions, including chronic lung disease, cardiovascular disease, chronic liver disease, severe obesity, and diabetes.1
You can access the FDA's policy position on COVID-19 vaccination to see the list of medical conditions that increase risk of severe COVID-19. For further information. consult your national and local health authorities.
NUVAXOVID is the only non-mRNA, protein-based COVID-19 vaccine option you can offer to eligible patients regardless of the previous COVID-19 vaccines they received.1
INDICATION
References
1. NUVAXOVID. Prescribing Information. Novavax, Inc. 2. Roper LE, Godfrey M, Link-Gelles R, et al. Use of additional doses of 2024-2025 COVID-19 vaccine for adults aged ≥65 years and persons aged ≥6 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(49):1118-1123. 3. Panagiotakopoulos L, Moulia DL, Godfrey M, et al. Use of COVID-19 vaccines for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices—United States, 2024-2025. MMWR Morb Mortal Wkly Rep. 2024 Sep 19;73(37):819-824. doi:10.15585/mmwr. mm7337e2
